The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency
Autosomal Recessive Hypophosphatemic Rickets
Generalized Arterial Calcification of Infancy

Interventions

DRUG: INZ-701
DRUG: Control Arm (Conventional Therapy)

Sponsor

Inozyme Pharma